Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • VE-821 ATR Kinase Inhibitor: Evidence & Limits

    2026-10-05

    VE-821 ATR Kinase Inhibitor: Evidence & Limits

    Executive Summary. VE-821 is described as a selective, ATP-competitive ATR kinase inhibitor for DNA damage response research in the product dossier. The same source reports a dissociation constant of 13 nM and an ATR inhibition concentration of 26 nM, although the supplied product page does not specify the assay buffer, temperature, or incubation time for those values product evidence. The product description associates VE-821 with reduced ATR-mediated Chk1 phosphorylation at Ser345 and increased radiation or chemotherapy response in listed cancer cell models catalog-reported findings. A peer-reviewed HBoV1 study found that DNMT1-dependent DNA methylation supported viral DNA replication while NS1-mediated DNMT1 degradation altered viral RNA processing Qin et al., 2024. That HBoV1 study did not establish that VE-821 affects DNMT1, NS1, or HBoV1 biology primary study.

    Biological Rationale

    ATR is a protein kinase in the DNA damage response. It responds to replication-associated stress and contributes to checkpoint signaling through downstream effectors that include Chk1. A selective ATR perturbation can therefore serve as a research tool for examining how cells coordinate DNA replication, damage sensing, checkpoint control, and survival.

    VE-821 is relevant to DNA repair pathway research because its reported target is ATR rather than DNMT1. This distinction matters when interpreting studies that combine DNA damage, epigenetic regulation, and viral replication. A change in DNA synthesis, RNA processing, or cell survival is not automatically evidence of a shared mechanism.

    Qin and colleagues studied human bocavirus 1, or HBoV1, a small single-stranded DNA virus associated with respiratory disease in young children. Their 2024 PLOS Pathogens article reported extensive methylation of HBoV1 genomic DNA at CHG and CHH sites. The authors further reported that inhibiting DNA methylation or reducing DNMT1 changed viral DNA production and RNA processing Qin et al., 2024.

    The biological rationale for placing these topics together is comparative, not confirmatory. ATR signaling represents a host DNA damage checkpoint axis. DNMT1 represents a DNA methylation axis. The HBoV1 paper provides evidence for the second axis but does not validate VE-821 as an HBoV1-active compound.

    Mechanism of Action of VE-821

    APExBIO describes VE-821 as an ATP-competitive inhibitor of ATR. ATP competition means that the compound is presented as binding within the kinase catalytic site, where ATP normally participates in phosphate transfer. This description is a product-level pharmacology claim and should not be treated as a complete selectivity profile.

    The supplied dossier reports a Ki of 13 nM and an IC50 of 26 nM against ATR. These values are concentration units, but the product page does not provide the underlying assay temperature, buffer composition, pH, substrate concentration, or incubation duration. Consequently, the numbers support a potency benchmark for catalog comparison, not a universal prediction of cellular activity.

    The product description also reports minimal cross-reactivity toward mTOR, DNA-PK, PI3K-γ, and ATM. Because the supplied source does not provide a complete kinase panel, replicate information, or assay conditions, the selectivity statement should be interpreted as reported product metadata rather than an exhaustive independent validation.

    One reported downstream consequence is reduced ATR-mediated phosphorylation of Chk1 at Ser345. Chk1 Ser345 is therefore a useful pathway-linked readout when the research question concerns ATR checkpoint signaling. It is not, by itself, proof that every downstream phenotype is caused exclusively by ATR inhibition. Cellular stress, DNA damage burden, compound exposure, and model-specific pathway wiring can influence the same endpoint.

    Evidence & Benchmarks

    The evidence base has two different levels. The VE-821 information comes from a product description. The HBoV1 information comes from a peer-reviewed primary research article. The sources should not be treated as interchangeable.

    • VE-821 is described as a potent and selective ATP-competitive ATR kinase inhibitor. Product dossier
    • The reported ATR potency benchmarks are Ki 13 nM and IC50 26 nM; the supplied source does not state the assay temperature, buffer, pH, or incubation time. Product dossier
    • The product description associates VE-821 with reduced ATR-mediated Chk1 phosphorylation at Ser345 in cellular research contexts. Product dossier
    • The catalog description lists radiosensitization-related findings in HL-60, PSN-1, MiaPaCa-2, HFL1, HCT116, and H23 cell models; it does not provide a complete comparative dataset in the supplied dossier. Product dossier
    • The product description reports increased cytotoxic responses when VE-821 is studied with gemcitabine or cisplatin, including under hypoxic conditions; the supplied page does not establish a general combination rule across models. Product dossier
    • HBoV1 genomic DNA was reported to contain extensive CHG and CHH methylation in the 2024 study. Qin et al., 2024
    • DNA-methylation inhibition and DNMT1 knockdown were reported to reduce HBoV1 DNA production and alter viral RNA processing. Qin et al., 2024
    • HBoV1 NS1 was reported to promote DNMT1 degradation through the ubiquitin-proteasome pathway. Qin et al., 2024

    Applications, Limits & Misconceptions

    Research applications

    VE-821 can be framed as a mechanistic probe for ATR checkpoint biology. A radiosensitization assay using VE-821 asks whether ATR pathway inhibition changes the response of a defined cellular model to radiation. A chemotherapy sensitization study asks whether ATR perturbation changes the response to a selected cytotoxic agent. These are research questions, not universal properties of every cell line or treatment combination.

    The product dossier lists activity in several cancer cell models and reports associations with gemcitabine, cisplatin, and hypoxic conditions catalog evidence. Those observations support hypothesis generation around replication stress and checkpoint dependence. They do not establish that VE-821 will produce the same response in primary cells, organoids, animal models, or clinical tumors.

    The HBoV1 paper suggests a separate research direction. A conceptual cross-domain study could ask whether ATR pathway status changes the cellular response to HBoV1-associated molecular processes while measuring DNMT1 abundance, methylation state, and RNA-processing outcomes as distinct endpoints. Such a design would need to distinguish direct ATR effects from changes in cell viability, DNA damage, methylation, or viral RNA maturation. The 2024 paper does not provide that comparison.

    Common Pitfalls or Misconceptions

    1. Misconception: VE-821 is a DNMT1 inhibitor. The supplied product description identifies ATR as the target. The HBoV1 study identifies DNMT1 as a host methyltransferase involved in its model. No cited source demonstrates that VE-821 directly inhibits DNMT1.
    2. Misconception: ATR inhibition and DNA methylation inhibition are interchangeable. They represent different molecular perturbations. Similar changes in DNA production or cell survival would require direct pathway measurements before a shared mechanism could be claimed.
    3. Misconception: A product-reported IC50 predicts every cellular response. The reported 26 nM value is an ATR assay benchmark. Cellular activity depends on model, exposure, target engagement, pathway state, and assay design, and the supplied page does not specify all of those variables.
    4. Misconception: Radiosensitization is guaranteed across cancer types. The product dossier reports selected cell models, not a universal response. Radiosensitization remains a model-dependent phenotype.
    5. Misconception: The HBoV1 paper validates VE-821 for antiviral research. The paper studied methylation, DNMT1, NS1, replication, and RNA processing. It did not report VE-821 as an intervention Qin et al., 2024.

    Research Context & Evidence Limitations

    A defensible research workflow would treat VE-821 as an ATR-pathway perturbation and would keep pathway readouts separate from phenotype readouts. ATR or Chk1 signaling markers can address target-pathway engagement. DNA synthesis, RNA processing, methylation, and viability measurements address different biological layers. The interpretation becomes stronger when those layers are not collapsed into a single endpoint.

    The evidence hierarchy also matters. The HBoV1 findings are from a peer-reviewed, open-access PLOS Pathogens research article with stated data availability and transparent provenance Qin et al., 2024. The VE-821 potency and application claims cited here come from a commercial product page. They are useful for product identification and reported benchmark values, but they are not a substitute for a complete primary pharmacology publication.

    The related article VE-821 ATR Kinase Inhibitor: Precision in DDR Research emphasizes assay optimization and troubleshooting; this article instead clarifies evidence provenance and avoids procedural guidance. The article VE-821 ATR Kinase Inhibitor: Applied Workflows presents a practical framing of ATR, radiation, and chemotherapy response; this article narrows the discussion to conceptual interpretation and source-supported limits. The article VE-821: A Decision Framework for ATR Biology discusses separation of ATR and DNMT1 questions; this article updates that boundary with the 2024 HBoV1 findings and their specific lack of VE-821 evidence.

    A key applicability boundary is that HBoV1 is a viral model with distinctive genome methylation and RNA-processing biology. Findings from HBoV1 cannot be transferred directly to human cancer models. Conversely, radiosensitization or chemotherapy sensitization in cancer cell lines cannot be used to infer antiviral activity.

    Conclusion & Outlook

    VE-821 is best described as a research compound for interrogating ATR kinase and DNA damage checkpoint biology. The supplied product evidence supports ATR potency, Chk1 Ser345 pathway effects, and selected reports of radiosensitization and chemotherapy sensitization. The strength of those claims is limited by the absence of full assay conditions and a complete independent pharmacology dataset.

    The HBoV1 study provides strong, peer-reviewed evidence for a DNMT1-centered mechanism involving DNA methylation, viral DNA production, RNA processing, and NS1-associated DNMT1 degradation Qin et al., 2024. It does not establish a connection to ATR inhibition. Future cross-domain work should therefore test that connection directly rather than infer it from overlapping DNA or stress phenotypes.

    For citation-aware interpretation, the most accurate summary is simple: VE-821 is an ATR kinase inhibitor with product-reported checkpoint and sensitization applications, while DNMT1-mediated HBoV1 regulation is a separate evidence stream. Keeping those statements distinct improves reproducibility, model interpretation, and responsible use of the literature.